keyword
MENU ▼
Read by QxMD icon Read
search

Monica morrow

keyword
https://www.readbyqxmd.com/read/28334423/are-there-patients-with-t1-to-t2-lymph-node-negative-breast-cancer-who-are-high-risk-for-locoregional-disease-recurrence
#1
Anita Mamtani, Sujata Patil, Michelle M Stempel, Monica Morrow
BACKGROUND: Indications for postmastectomy radiotherapy (PMRT) in patients with T1 to T2, lymph node-negative (N0) breast cancer with "high-risk" features are controversial. The European Organization for Research and Treatment of Cancer (EORTC) 22922 and National Cancer Institute of Canada Clinical Trials Group MA20 trials reporting improved 10-year disease-free survival with lymph node irradiation included patients with high-risk N0 disease, but, to the authors' knowledge, benefits in patients receiving modern systemic therapy are uncertain...
March 23, 2017: Cancer
https://www.readbyqxmd.com/read/28332033/surgeon-attitudes-and-use-of-mri-in-patients-newly-diagnosed-with-breast-cancer
#2
Monica Morrow, Sarah T Hawley, M Chandler McLeod, Ann S Hamilton, Kevin C Ward, Steven J Katz, Reshma Jagsi
BACKGROUND: Usage of magnetic resonance imaging (MRI) in newly diagnosed breast cancer patients is increasing, despite scant evidence that it improves outcomes. Little is known about the knowledge, perspectives, and clinical characteristics of surgeons associated with MRI use. METHODS: Women with early-stage breast cancer undergoing definitive surgery between July 2013 and August 2015 were identified from the Los Angeles and Georgia Surveillance, Epidemiology and End Results (SEER) registries and were asked to name their attending surgeons...
March 22, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28329092/secretor-and-salivary-abo-blood-group-antigen-status-predict-rotavirus-vaccine-take-in-infants
#3
Abdul Momin Kazi, Margaret M Cortese, Ying Yu, Benjamin Lopman, Ardythe L Morrow, Jessica A Fleming, Monica M McNeal, A Duncan Steele, Umesh D Parashar, Anita K M Zaidi, Asad Ali
Histo-blood group antigens (HBGA) expressed on enterocytes are proposed receptors for rotaviruses and can be measured in saliva. Among 181 Pakistani infants in a G1P[8] rotavirus vaccine trial that were seronegative at baseline, anti-rotavirus IgA seroconversion rates after 3 vaccine doses differed significantly by HBGA phenotype: lowest (19%) among infants who were non-secretors (ie, do not express the carbohydrate synthesized by FUT2 gene), intermediate among non-blood group O secretors (30%) and highest (51%) among O-blood group secretors...
January 18, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28327961/evaluation-of-breast-tissue-with-confocal-strip-mosaicking-microscopy-a-test-approach-emulating-pathology-like-examination
#4
Sanjee Abeytunge, Bjorg Larson, Gary Peterson, Monica Morrow, Milind Rajadhyaksha, Melissa P Murray
No abstract text is available yet for this article.
March 1, 2017: Journal of Biomedical Optics
https://www.readbyqxmd.com/read/28323914/menopause-is-a-determinant-of-breast-aromatase-expression-and-its-associations-with-bmi-inflammation-and-systemic-markers
#5
Kristy A Brown, Neil M Iyengar, Xi Kathy Zhou, Ayca Gucalp, Kotha Subbaramaiah, Hanhan Wang, Dilip D Giri, Monica Morrow, Domenick J Falcone, Nils K Wendel, Lisle A Winston, Michael Pollak, Anneloor Dierickx, Clifford A Hudis, Andrew J Dannenberg
CONTEXT: Most estrogen-dependent breast cancers occur after menopause despite low levels of circulating estrogens. Breast expression of the estrogen-biosynthetic enzyme, aromatase, is proposed to drive breast cancer development after menopause. However, the effects of menopause on breast aromatase expression are unknown. OBJECTIVE: To determine the effect of menopause on breast aromatase expression in relation to body mass index (BMI), white adipose tissue inflammation (WATi) and systemic markers of metabolic dysfunction...
February 16, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28270386/metabolic-obesity-adipose-inflammation-and-elevated-breast-aromatase-in-women-with-normal-body-mass-index
#6
Neil M Iyengar, Kristy A Brown, Xi Kathy Zhou, Ayca Gucalp, Kotha Subbaramaiah, Dilip D Giri, Heba Zahid, Priya Bhardwaj, Nils K Wendel, Domenick J Falcone, Hanhan Wang, Samantha Williams, Michael Pollak, Monica Morrow, Clifford A Hudis, Andrew J Dannenberg
Obesity is associated with breast white adipose tissue (WAT) inflammation, elevated levels of the estrogen biosynthetic enzyme, aromatase, and systemic changes that have been linked to the pathogenesis of breast cancer. Here, we determined whether metabolic obesity, including changes in breast biology and systemic effects, occurs in a subset of women with normal body mass index (BMI). Breast WAT and fasting blood were collected from 72 women with normal BMI (<25 kg/m(2)) undergoing mastectomy for breast cancer risk reduction or treatment...
March 7, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28170472/genetic-testing-and-counseling-among-patients-with-newly-diagnosed-breast-cancer
#7
LETTER
Allison W Kurian, Kent A Griffith, Ann S Hamilton, Kevin C Ward, Monica Morrow, Steven J Katz, Reshma Jagsi
No abstract text is available yet for this article.
February 7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28167568/pathologic-complete-response-with-neoadjuvant-doxorubicin-and-cyclophosphamide-followed-by-paclitaxel-with-trastuzumab-and-pertuzumab-in-patients-with-her2-positive-early-stage-breast-cancer-a-single-center-experience
#8
Jasmeet C Singh, Anita Mamtani, Andrea Barrio, Monica Morrow, Steven Sugarman, Lee W Jones, Anthony F Yu, Daniel Argolo, Lilian M Smyth, Shanu Modi, Sarah Schweber, Camilla Boafo, Sujata Patil, Larry Norton, Jose Baselga, Clifford A Hudis, Chau Dang
OBJECTIVES: Trastuzumab (H) and pertuzumab (P) with standard chemotherapy is approved for use in the neoadjuvant setting for human epidermal growth receptor 2 -positive patients. A retrospective analysis was performed of patients treated with dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T), trastuzumab, and pertuzumab (THP) in the neoadjuvant setting. Here, the pathologic complete response (pCR) rates are reported. METHODS: An electronic medical record review was conducted of patients treated with HP-based therapy in the neoadjuvant setting from September 1, 2013, to March 1, 2015...
February 2017: Oncologist
https://www.readbyqxmd.com/read/28160790/trends-and-controversies-in-multidisciplinary-care-of-the-patient-with-breast-cancer
#9
REVIEW
Laura S Dominici, Monica Morrow, Elizabeth Mittendorf, Jennifer Bellon, Tari A King
No abstract text is available yet for this article.
December 2016: Current Problems in Surgery
https://www.readbyqxmd.com/read/28160789/in-brief
#10
Laura S Dominici, Monica Morrow, Elizabeth Mittendorf, Jennifer Bellon, Tari A King
No abstract text is available yet for this article.
December 2016: Current Problems in Surgery
https://www.readbyqxmd.com/read/28152973/multidisciplinary-process-improvement-to-optimize-oral-chemotherapy-safety
#11
Kerin B Adelson, Monica Fradkin, Renee Havriliak, Michelle Renee Harrison, Osama Abdelghany, Stephanie Kregling, Jessica Wright, Bret Morrow, Roberta Sterling, Mandeep Smith, Frank Esposito, Martha Stutsky, LeeAnn Miller, Rogerio Lilenbaum, Catherine A Lyons, Anne C Chiang, Howard Cohen
134 Background: The rapid development of oral chemotherapy agents brings unique challenges. These drugs must be treated with the same vigilance as parenteral chemotherapy. The oral chemotherapy system is not optimized or integrated across our hospital. A quality assessment survey identified the need for a better means to monitor and improve oral chemotherapy patient outcomes. METHODS: Patient and staff satisfaction with the current process was measured. A chartered multidisciplinary task force reviewed existing practice and developed a program to identify patients, ensure drug access, standardize prescription and consent, ensure on-going clinical support including patient education, regimen specific adherence monitoring, toxicity assessment and address patient concerns...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152879/contralateral-prophylactic-mastectomy-decision-making-in-the-population-based-icancare-study-of-early-stage-breast-cancer-patients
#12
Sarah T Hawley, Kent A Griffith, Nancy K Janz, Allison W Kurian, Kevin C Ward, Ann S Hamilton, Steven J Katz, Monica Morrow
177 Background: Contralateral prophylactic mastectomy (CPM) use is increasing in women who are not at increased risk of contralateral cancer development and will experience no survival benefit from the more morbid procedure. Little is known about treatment decision-making or provider interactions. METHODS: We surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer who were treated in 2013-14, identified through the population-based SEER registries of Los Angeles and Georgia about 3 months after surgical treatment, and merged with SEER data (N=2632, RR=70%), to determine receipt of diagnostic tests and factors related to the decision about surgery (including knowledge and perceived physician recommendation)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152870/recurrence-risk-perception-and-quality-of-life-after-treatment-of-breast-cancer
#13
Nancy K Janz, Reshma Jagsi, Kent A Griffith, Christopher Ryan Friese, Allison W Kurian, Monica Morrow, Lauren P Wallner, Steven J Katz
175 Background: Many breast cancer patients overestimate their risk of distant recurrence after treatment. We explored risk perception in a large, diverse population of breast cancer patients with favorable prognosis and assessed associations between overestimation and quality of life (QoL). METHODS: As part of the iCanCare Study, we surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer treated in 2013-14, identified through the population-based SEER registries of Los Angeles & Georgia about 3 months after surgical treatment (N = 2632, RR = 70%)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28132390/impact-of-self-reported-data-on-the-acquisition-of-multi-generational-family-history-and-lifestyle-factors-among-women-seen-in-a-high-risk-breast-screening-program-a-focus-on-modifiable-risk-factors-and-genetic-referral
#14
Laura H Rosenberger, Ryan Weber, Daniel Sjoberg, Andrew J Vickers, Debra A Mangino, Monica Morrow, Melissa L Pilewskie
BACKGROUND: The phrase "high-risk for breast cancer" is used to identify various groups at elevated cancer risk, and the appropriate surveillance and risk-reducing strategies differ based on the etiology of risk. Here, we review the utility of patient-reported data to capture women with modifiable lifestyle risk factors and those suitable for genetic counseling referral. METHODS: Patient-reported data from a web-based survey were used to capture personal history, multi-generational family history, and lifestyle factors (body mass index, alcohol consumption, physical activity)...
April 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28130619/is-routine-axillary-imaging-necessary-in-clinically-node-negative-patients-undergoing-neoadjuvant-chemotherapy
#15
Andrea V Barrio, Anita Mamtani, Anne Eaton, Sandra Brennan, Michelle Stempel, Monica Morrow
BACKGROUND: The National Comprehensive Cancer Network guidelines recommend axillary imaging prior to neoadjuvant chemotherapy (NAC) in breast cancer patients who are clinically node negative (cN0) by physical examination. However, the benefit of this approach remains uncertain. The purpose of this study was to determine whether abnormal axillary imaging pre-NAC predicts nodal metastases post-NAC (ypN+) in cN0 patients. METHODS: cN0 patients undergoing NAC followed by axillary surgery were identified...
March 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28121514/genetic-drivers-of-kidney-defects-in-the-digeorge-syndrome
#16
Esther Lopez-Rivera, Yangfan P Liu, Miguel Verbitsky, Blair R Anderson, Valentina P Capone, Edgar A Otto, Zhonghai Yan, Adele Mitrotti, Jeremiah Martino, Nicholas J Steers, David A Fasel, Katarina Vukojevic, Rong Deng, Silvia E Racedo, Qingxue Liu, Max Werth, Rik Westland, Asaf Vivante, Gabriel S Makar, Monica Bodria, Matthew G Sampson, Christopher E Gillies, Virginia Vega-Warner, Mariarosa Maiorana, Donald S Petrey, Barry Honig, Vladimir J Lozanovski, Rémi Salomon, Laurence Heidet, Wassila Carpentier, Dominique Gaillard, Alba Carrea, Loreto Gesualdo, Daniele Cusi, Claudia Izzi, Francesco Scolari, Joanna A E van Wijk, Adela Arapovic, Mirna Saraga-Babic, Marijan Saraga, Nenad Kunac, Ali Samii, Donna M McDonald-McGinn, Terrence B Crowley, Elaine H Zackai, Dorota Drozdz, Monika Miklaszewska, Marcin Tkaczyk, Przemyslaw Sikora, Maria Szczepanska, Malgorzata Mizerska-Wasiak, Grazyna Krzemien, Agnieszka Szmigielska, Marcin Zaniew, John M Darlow, Prem Puri, David Barton, Emilio Casolari, Susan L Furth, Bradley A Warady, Zoran Gucev, Hakon Hakonarson, Hana Flogelova, Velibor Tasic, Anna Latos-Bielenska, Anna Materna-Kiryluk, Landino Allegri, Craig S Wong, Iain A Drummond, Vivette D'Agati, Akira Imamoto, Jonathan M Barasch, Friedhelm Hildebrandt, Krzysztof Kiryluk, Richard P Lifton, Bernice E Morrow, Cecile Jeanpierre, Virginia E Papaioannou, Gian Marco Ghiggeri, Ali G Gharavi, Nicholas Katsanis, Simone Sanna-Cherchi
Background The DiGeorge syndrome, the most common of the microdeletion syndromes, affects multiple organs, including the heart, the nervous system, and the kidney. It is caused by deletions on chromosome 22q11.2; the genetic driver of the kidney defects is unknown. Methods We conducted a genomewide search for structural variants in two cohorts: 2080 patients with congenital kidney and urinary tract anomalies and 22,094 controls. We performed exome and targeted resequencing in samples obtained from 586 additional patients with congenital kidney anomalies...
February 23, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28117882/treatment-associated-toxicities-reported-by-patients-with-early-stage-invasive-breast-cancer
#17
Christopher R Friese, Jordan M Harrison, Nancy K Janz, Reshma Jagsi, Monica Morrow, Yun Li, Ann S Hamilton, Kevin C Ward, Allison W Kurian, Steven J Katz, Timothy P Hofer
BACKGROUND: Patient-reported toxicities help to appraise the breast cancer treatment experience. Yet extant data come from clinical trials and health care claims, which may be biased. Using patient surveys, the authors sought to quantify the frequency, severity, and burden of treatment-associated toxicities. METHODS: Between 2013 and 2014, the iCanCare study surveyed a population-based sample of women residing in Los Angeles County and Georgia with early-stage, invasive breast cancer...
January 24, 2017: Cancer
https://www.readbyqxmd.com/read/28068171/reply-to-l-b-marks-et-al
#18
Abram Recht, Elizabeth A Comen, Richard E Fine, Gini F Fleming, Patricia H Hardenbergh, Alice Y Ho, Clifford A Hudis, E Shelley Hwang, Jeffrey J Kirshner, Monica Morrow, Kilian E Salerno, George W Sledge, Lawrence J Solin, Patricia A Spears, Timothy J Whelan, Mark R Somerfield, Stephen B Edge
No abstract text is available yet for this article.
January 9, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28058550/do-calcifications-seen-on-mammography-after-neoadjuvant-chemotherapy-for-breast-cancer-always-need-to-be-excised
#19
Yara Feliciano, Anita Mamtani, Monica Morrow, Michelle M Stempel, Sujata Patil, Maxine S Jochelson
BACKGROUND: This study aimed to determine the relationship between mammographic calcifications and magnetic resonance imaging (MRI) tumoral enhancement before and after neoadjuvant chemotherapy (NAC) and to assess the impact of these findings on surgical management. METHODS: This Institutional Review Board-approved, Health Insurance Portability and Accountability Act (HIPAA)-compliant retrospective study involved breast cancer patients who underwent NAC between 2009 and 2015...
January 5, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28004220/recurrence-risk-perception-and-quality-of-life-following-treatment-of-breast-cancer
#20
Sarah T Hawley, Nancy K Janz, Kent A Griffith, Reshma Jagsi, Christopher R Friese, Allison W Kurian, Ann S Hamilton, Kevin C Ward, Monica Morrow, Lauren P Wallner, Steven J Katz
PURPOSE: Little is known about different ways of assessing risk of distant recurrence following cancer treatment (e.g., numeric or descriptive). We sought to evaluate the association between overestimation of risk of distant recurrence of breast cancer and key patient-reported outcomes, including quality of life and worry. METHODS: We surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer identified through SEER registries of Los Angeles County & Georgia (2013-14) ~2 months after surgery (N = 2578, RR = 71%)...
February 2017: Breast Cancer Research and Treatment
keyword
keyword
110606
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"